← Eichor
Condition: Advanced Solid Tumor Phase 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Solid Tumor Phase 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Trutino Biosciences Inc. · NCT06770764A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Phase 2 · 1 location(s) · Zhejiang Wenda Pharma Technology LTD. · NCT06527300A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Phase 1 · 10 location(s) · Janssen Research & Development, LLC · NCT07107230A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · 19 location(s) · Merck Sharp & Dohme LLC · NCT07247110A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injectio
Phase 1 · 65 location(s) · GlaxoSmithKline · NCT06431594A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Vibrant Sciences Limited · NCT07222969Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT07265622Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06921928Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Phase 1 · 2 location(s) · Chipscreen Biosciences, Ltd. · NCT06902350Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06820424A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1 · 19 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06859762A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Proviva Therapeutics, Inc. · NCT06190886A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Shanghai Henlius Biotech · NCT07473726Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Phase 1 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07134998Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07656116A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima
Phase 1 · 3 location(s) · Kangabio AUSTRALIA LTD PTY · NCT07260305A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562A Study of HG381 Administered to Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · HitGen Inc. · NCT04998422A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of
Phase 1/Phase 2 · 12 location(s) · Ipsen · NCT07213817A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 39 location(s) · Incyte Corporation · NCT05836324A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Phase 1/Phase 2 · 14 location(s) · Krystal Biotech, Inc. · NCT06228326HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.